Vancouver, British Columbia / ACCESSWIRE / August 8, 2014 / Vodis Pharmaceuticals Inc. (the "Company" or "Vodis") (CSE: VP) announces that it has canceled its 10% rolling stock option plan and established a 20% fixed stock option plan (the "2014 Plan") under which options to purchase common shares in the capital stock of the Company may be granted from time to time to directors, senior officers, employees and other persons eligible to be granted options in accordance with the policies of the CSE. A total of 9,710,000 shares have been reserved for issuance under the 2014 Plan.
Additionally, the Company has granted incentive stock options (the "Stock Options") pursuant to the New Plan to consultants of the Company (the "Optionees") entitling the purchase of an aggregate 500,000 common shares. The Stock Options are exercisable at a price of $0.40 for a period of 10 years.
About Vodis
Vodis is one of Canada's foremost brand names in the medical marijuana business. Our products have consistently won or placed at each competition we have entered. The company is in the application process to become a Licenced Producer at our 12,000 square foot facility in Canada.
We seek Safe Harbor.
For further information please contact:
Brian Gusko
CFO & Director
Vodis Pharmaceuticals
104-1037 West Broadway
Vancouver, BC V6H 1E3
direct: 604-727-1295
web: www.vodis.ca
The CSE has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.
SOURCE: Vodis Pharmaceuticals Inc.